期刊
ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE
卷 2, 期 6, 页码 372-386出版社
AMER CHEMICAL SOC
DOI: 10.1021/acsptsci.9b00068
关键词
remyelination pharmacotherapies; oligodendrocytes; OPCs; multiple sclerosis; inflammation
资金
- Patrick Healy Graduate Fellowship from Georgetown University Graduate School of Arts Sciences
- National Multiple Sclerosis Society Harry Weaver Neuroscience Scholars fellowship [JF-1806-31381]
- National Institutes of Health [1R01NS10752301]
- CDMRP/DOD [W81XWH-17-1-0268]
Multiple sclerosis (MS) is an immune-mediated disease of the central nervous system characterized by a complex lesion microenvironment. Although much progress has been made in developing immunomodulatory treatments to reduce myelin damage and delay the progression of MS, there is a paucity in treatment options that address the multiple pathophysiological aspects of the disease. Currently available immune-centered therapies are able to reduce the immune-mediated damage exhibited in MS patients, however, they cannot rescue the eventual failure of remyelination or permanent neuronal damage that occurs as MS progresses. Recent advances have provided a better understanding of remyelination processes, specifically oligodendrocyte lineage cell progression following demyelination. Further there have been new findings highlighting various components of the lesion microenvironment that contribute to myelin repair and restored axonal health. In this review we discuss the complexities of myelin repair following immune-mediated damage in the CNS, the contribution of animal models of MS in providing insight on OL progression and myelin repair, and current and potential remyelination-centered therapeutic targets. As remyelination therapies continue to progress into clinical trials, we consider a dual approach targeting the inflammatory microenvironment and intrinsic remyelination mechanisms to be optimal in aiding MS patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据